Sunday 18 October 2026
Export CCCC’s income statement to Excel — free account
C4 Therapeutics, Inc.
CCCC Healthcare Biotechnology
C4 Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $35.9 million, up 1.02% from fiscal 2024. In the quarter to June 2026, revenue grew 2.75%, EPS grew 51.4% and free cash flow grew 86.8%, each against the same quarter a year earlier.
2.77
0.01
−0.36%
Follow CCCC
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 3 | 2 | 3 | 2 | 4 | 4 |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | 1.85 | 7.06 | (0.31) | (1.11) | (1.71) | (2.16) |
P/S ratio |
— | 1.30 | 1.30 | 11.35 | 32.38 | 10.03 | 15.59 | 7.02 | 4.40 |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | 1.38 | (1.76) | 5.49 | 4.23 | 0.83 | (1.09) | (2.52) | (2.12) |
Beneish M-Score |
— | — | — | (2.44) | 0.89 | (3.67) | 6.90 | (3.16) | (2.61) |
P/Operating CF |
— | (2.73) | (2.73) | (17.44) | (57.75) | (10.70) | (13.48) | (13.93) | (7.15) |
P/B ratio |
— | 0.00 | 0.00 | 1.34 | 3.81 | 1.08 | 1.32 | 1.16 | 0.62 |
Price to Tangible BV |
— | 0.00 | 0.00 | 1.34 | 3.81 | 1.08 | 1.32 | 1.16 | 0.62 |
EV/Sales |
— | (4.93) | (4.93) | 0.48 | 25.89 | 1.51 | 4.28 | 0.67 | (1.98) |
EV/EBITDA |
— | 2.98 | 2.98 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.61 |
EV/Operating CF |
— | 2.67 | 2.67 | (0.24) | (13.63) | (0.44) | (0.83) | (0.37) | 0.72 |
EV/FCF |
— | 2.66 | 2.66 | (0.24) | (13.43) | (0.42) | (0.82) | (0.36) | 0.72 |
Quick Ratio |
— | 5.13 | 2.83 | 8.58 | 6.15 | 6.23 | 6.21 | 5.49 | 7.60 |
Current Ratio |
— | 5.16 | 2.88 | 8.69 | 6.36 | 6.46 | 6.34 | 5.71 | 7.81 |
Net Debt/EBITDA |
— | 1.70 | 2.29 | 6.16 | 3.81 | 2.09 | 1.81 | 1.99 | 2.14 |
Debt/Assets |
0.00% | 9.89% | 11.63% | 2.77% | 2.39% | 2.67% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.46 | (14.20) | 0.04 | 0.03 | 0.04 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.26 | 0.16 | 0.13 | 0.10 | 0.07 | 0.05 | 0.10 | 0.10 |
Operating CF/Net income |
— | 0.70 | (1.31) | 1.01 | 1.04 | 0.83 | 0.81 | 0.62 | 0.94 |
Capex/Depreciation |
— | 0.00 | (0.67) | (0.34) | (0.31) | (1.77) | 1.14 | 0.05 | 0.78 |
Interest Coverage |
— | (47.85) | 16.44 | (72.31) | (46.72) | (58.45) | (101.26) | 8.29 | 11.13 |
| — | 25.15% | 44.41% | (78.58%) | (25.03%) | (37.76%) | (49.50%) | (45.58%) | (44.44%) | |
| — | (32.91%) | (32.16%) | (25.59%) | (18.50%) | (27.34%) | (32.82%) | (29.01%) | (29.63%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | (55.54%) | (329.60%) | 0.00% | 0.00% | (894.58%) |
Return on Tangible Assets |
— | (20.10%) | (62.98%) | (19.48%) | (30.23%) | (51.19%) | (56.25%) | (48.21%) | (45.68%) |
Average Days of Receivables |
— | 1,629.31 | 78.92 | 49.30 | 45.57 | 17.29 | 207.49 | 31.82 | 24.38 |
Research and Development Expense of Revenue |
— | 141.46% | 224.77% | 236.30% | 206.76% | 378.96% | 567.09% | 310.92% | 289.98% |
Selling, General and Administrative Expense of Revenue |
— | 24.73% | 41.04% | 45.80% | 72.63% | 137.60% | 202.74% | 118.38% | 100.69% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 7.68% | 10.34% | 46.98% | 96.53% | 131.22% | 83.36% | 53.13% |
Graham Net Nets |
— | 2.05 | 2.05 | 0.69 | 0.14 | 0.47 | 0.44 | 0.50 | 0.98 |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | (158.26%) | (158.26%) | (27.81%) | (5.65%) | (41.07%) | (40.95%) | (41.94%) | (71.20%) |
Free Cash Flow Yield |
— | (143.03%) | (143.03%) | (18.03%) | (5.95%) | (35.75%) | (33.54%) | (26.22%) | (62.72%) |
Revenue per Share |
— | 0.46 | 15.58 | 2.92 | 0.99 | 0.64 | 0.42 | 0.51 | 0.43 |
Operating CF per Share |
— | (0.40) | 40.54 | (5.91) | (1.89) | (2.17) | (2.15) | (0.94) | (1.19) |
Capex per Share |
— | 0.00 | (0.94) | (0.06) | (0.03) | (0.11) | (0.03) | 0.00 | (0.01) |
Free Cash Flow per Share |
— | (0.40) | 39.60 | (5.97) | (1.92) | (2.28) | (2.19) | (0.94) | (1.20) |
Cash per Share |
— | 0.86 | 66.00 | 32.69 | 6.72 | 5.65 | 5.11 | 3.53 | 3.00 |
Shareholders Equity per Share |
— | 0.74 | (0.71) | 24.70 | 8.46 | 5.92 | 4.96 | 3.11 | 3.10 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.74 | (0.71) | 24.70 | 8.46 | 5.92 | 4.96 | 3.11 | 3.10 |
Free Cash Flow |
— | (16.98) | 54.33 | (67.90) | (88.24) | (111.43) | (108.55) | (65.34) | (99.30) |
Working Capital |
— | 99.58 | 63.13 | 337.16 | 274.44 | 243.01 | 228.42 | 212.59 | 225.08 |
Capital Expenditures |
— | (2.69) | (1.29) | (0.65) | (1.28) | (5.50) | (1.71) | (0.18) | (0.61) |
Net Current Asset Value |
— | 8.28 | (22.46) | 261.66 | 208.53 | 145.95 | 140.85 | 124.15 | 155.62 |
EV/EBIT |
— | 2.90 | 2.90 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.62 |
Capex to Sales |
— | 0.00 | 0.06 | 0.02 | 0.03 | 0.18 | 0.08 | 0.01 | 0.02 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.18 | 0.43 | 0.58 | 1.32 | 0.42 | (0.21) | (0.61) | (0.17) |
Cash ROIC |
— | (20.70%) | 52.58% | (10.23%) | (12.41%) | (19.32%) | (21.72%) | (14.18%) | (19.66%) |
Accounts Receivable Turnover |
— | 0.43 | 0.47 | 7.29 | 8.98 | 8.65 | 3.13 | 4.78 | 13.06 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | 45.53 | 45.53 | 4.55 | 5.10 | 3.59 | 6.64 | 7.45 | 2.75 |
Average Payables |
— | 3.27 | 3.27 | 5.53 | 5.09 | 2.84 | 1.31 | 1.39 | 1.09 |
Average Assets |
— | 73.25 | 132.38 | 259.20 | 453.45 | 468.80 | 403.65 | 363.03 | 354.34 |
Average Common Equity |
— | (95.86) | (95.86) | 84.41 | 335.20 | 339.42 | 267.67 | 231.05 | 236.29 |
Columns are period end dates